B · Normal
On October 6th, U.S. stock Vaxcyte is now up 27%, having risen nearly 60% earlier. It was reported that the company’s pneumococcal vaccine has reached late-stage clinical trial targets.
Related telegraphs
[United Nations Secretary-General Condemns U.S. Sanctions on the International C
10-10 08:46
[U.S. Treasury Secretary: The U.S. national debt has climbed to about $41 trilli
10-10 08:23
[The United States relaxes federal registration requirements for silencers and s
10-10 07:47
[Russia denies the emergence of new cases at the Institute of Infectious Disease
10-10 07:22
[Overnight global news you need to know on Saturday: Trump said Russia will imme
10-10 06:32
[Micron Technology expanded its stock repurchase plan to US$35 billion in Decemb
10-10 04:41
Comments